MyFiziq announces integration of BCT and Active8me
In addition to last week's definitive agreement negotiated with Active8me Pty Ltd, MyFiziq Limited’s (ASX:MYQ) 50% owned joint-venture partner Body Composition Technologies Pty Ltd (BCT), has now signed definitive agreements with Active8me Pty Ltd, which will see the integration of the BCT platform into the Active8me health and wellness platform.
The agreements are identical in nature with the exception of the differing business verticals as BCT operates in the insurance, medical and government research segments.
The BCT Commercial Contract is the main commercial agreement between the parties pursuant to which BCT agrees, inter alia, to grant a licence to Active8me to use BCT’s licensed software development kits and related intellectual property to integrate them into the Active8me platform/technology.
In return, Active8me has agreed to pay certain user fees, data storage fees, support fees and incidental support fees to BCT.
The BCT Software Development Kit, End User License Agreement, BCT Support Agreement and BCT Data Processing Agreement are support agreements related to the BCT Commercial Contract.
BCT does not expect any immediate material financial return as a result of entering into the contracts.
However, as the Active8me platform which is integrated with the BCT SDKs is rolled out in Asia, BCT expects to start generating licence and other fees from the commercial arrangement, the financial returns of which cannot be forecast at this time.
The initial term of the contract is 12 months, renewable for consecutive further terms of two years unless terminated under various clauses contained in the contract.
Body Composition Technology private, cost-effective and accurate
Body Composition Technologies (BCT) is focused on developing a cost effective, easily accessible and reliable smartphone-based body composition and anthropometric measurement tool for governments, insurers, medical organisations and the medical research markets.
The group strives to deliver a private, cost effective and accurate method for our users to identify, classify and monitor some of the primary markers of chronic diseases such as type 2 diabetes, coronary heart disease and stroke.
This early screening, assessment and long-term monitoring of the primary markers of chronic disease, is essential for reducing the spiralling healthcare costs and improving the quality of life for billions of people worldwide.
The group works with its partners to give them better engagement and understanding of their consumers/populations whilst empowering them through the technology to make better health decisions which in turn should deliver better health outcomes and lower mortality rates.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.